BIORESTORATIVE THERAPIES INC (BRTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.15+2.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BRTX
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(15.3) + peer(0.2*4.9) + term(0.0) → 6.32% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Result of Operations and Financial Condition. On November 12, 2025, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025 (the “Press Release”). The Press Release also provided a business update and included details with regard to the conference call to be held to discuss the third quarter results. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information contained in the Pre…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Result of Operations and Financial Condition. On August 12, 2025, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025 (the “Press Release”). The Press Release also provided a business update and included details with regard to the conference call to be held to discuss the second quarter results. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information contained in the Press Re…
Result of Operations and Financial Condition. On May 14, 2025, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025 (the “Press Release”). The Press Release also provided a business update and included details with regard to the conference call to be held to discuss the first quarter results and business update. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information contained…
Result of Operations and Financial Condition. On March 27, 2025, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing that its financial results for the year ended December 31, 2024 will be released after market close on March 27, 2025 (the “Press Release”). The Press Release included details with regard to a conference call to be hosted by the Company’s management following the release. On the call, the Company’s management will review the financial results and pr…
above. On November 13, 2024, the Company issued a press release (the “Presentation Press Release”) announcing that additional preliminary 26 and 52 week blinded data from the ongoing Phase 2 clinical trial of BRTX-100 in subjects with chronic lumbar disc disease would be presented by Francisco Silva, the Company’s Vice President of Research and Development, at the Orthopaedic Research Society (ORS) Philadelphia Spine Research Society (PSRS) 7 th International Spine Research Symposium, taking…
Result of Operations and Financial Condition. On August 13, 2024, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2024 (the “Press Release”). The Press Release also provided a business update and included details with regard to the conference call to be held to discuss the second quarter results. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information contained in the Press Re…
Result of Operations and Financial Condition. On August 6, 2024, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing that its financial results for the second quarter ended June 30, 2024 will be released after market close on Tuesday, August 13, 2024 (the “Press Release”). The Press Release included details with regard to a conference call to be hosted by the Company’s management following the release. On the call, the Company’s management will review the financia…